| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = -$312,004 ) |
| | 2024 | 2021 | ANABIOS CORP | 3030 BUNKER HILL ST STE 312 | SAN DIEGO | CA | 92109-5754 | SAN DIEGO | USA | R44NS119036 | Development of a novel analgesic for mixed inflammatory and neuropathic pain states | 000 | 1 | NIH | 8/2/2024 | -$312,004 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2020 | ANABIOS CORPORATION | 3030 BUNKER HILL ST STE 312 | SAN DIEGO | CA | 92109-5754 | SAN DIEGO | USA | R43DA052947 | Development of a novel translational pain-drug screening platform for the generation of human-relevant data in preclinical pain drug discovery | 000 | 1 | NIH | 9/19/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2020 | ANABIOS CORPORATION | 3030 BUNKER HILL ST STE 312 | SAN DIEGO | CA | 92109-5754 | SAN DIEGO | USA | R44TR003162 | Development of an Integrated Platform for the Use of Adult Human Primary Cardiomyocytes in Preclinical Safety Assessment | 000 | 1 | NIH | 8/1/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,734,409 ) |
| | 2021 | 2021 | ANABIOS CORPORATION | 3030 BUNKER HILL ST STE 312 | SAN DIEGO | CA | 92109-5754 | SAN DIEGO | USA | R44NS119036 | Development of a novel analgesic for mixed inflammatory and neuropathic pain states | 000 | 1 | NIH | 9/15/2021 | $1,734,409 |
| | 2021 | 2019 | ANABIOS CORPORATION | 3030 BUNKER HILL ST STE 312 | SAN DIEGO | CA | 92109-5754 | SAN DIEGO | USA | U01FD006879 | DEVELOPMENT AND QUALIFICATION OF A BIOMARKER FOR PRECLINICALLY IDENTIFYING THE PRO-ARRHYTHMIA RISK OF DRUGS BASED ON CONTRACTILITY MEASUREMENTS CONDUCTED IN HUMAN ADULT PRIMARY CARDIOMYOCYTES | 000 | 1 | FDA | 2/2/2021 | $0 |
| | 2021 | 2019 | ANABIOS CORPORATION | 3030 BUNKER HILL ST STE 312 | SAN DIEGO | CA | 92109-5754 | SAN DIEGO | USA | U01FD006879 | DEVELOPMENT AND QUALIFICATION OF A BIOMARKER FOR PRECLINICALLY IDENTIFYING THE PRO-ARRHYTHMIA RISK OF DRUGS BASED ON CONTRACTILITY MEASUREMENTS CONDUCTED IN HUMAN ADULT PRIMARY CARDIOMYOCYTES | 001 | 1 | FDA | 7/8/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,452,343 ) |
| | 2020 | 2020 | ANABIOS CORPORATION | 3030 BUNKER HILL ST STE 312 | SAN DIEGO | CA | 92109-5754 | SAN DIEGO | USA | R43DA052947 | Development of a novel translational pain-drug screening platform for the generation of human-relevant data in preclinical pain drug discovery | 000 | 1 | NIH | 9/15/2020 | $320,054 |
| | 2020 | 2020 | ANABIOS CORPORATION | 3030 BUNKER HILL ST STE 312 | SAN DIEGO | CA | 92109-5754 | SAN DIEGO | USA | R44TR003162 | Development of an Integrated Platform for the Use of Adult Human Primary Cardiomyocytes in Preclinical Safety Assessment | 000 | 1 | NIH | 3/4/2020 | $1,132,289 |
| | 2020 | 2019 | ANABIOS CORPORATION | 3030 BUNKER HILL ST STE 312 | SAN DIEGO | CA | 92109-5754 | SAN DIEGO | USA | U01FD006879 | DEVELOPMENT AND QUALIFICATION OF A BIOMARKER FOR PRECLINICALLY IDENTIFYING THE PRO-ARRHYTHMIA RISK OF DRUGS BASED ON CONTRACTILITY MEASUREMENTS CONDUCTED IN HUMAN ADULT PRIMARY CARDIOMYOCYTES | 000 | 1 | FDA | 8/20/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $247,461 ) |
| | 2019 | 2019 | ANABIOS CORPORATION | 3030 BUNKER HILL ST STE 312 | SAN DIEGO | CA | 92109-5754 | SAN DIEGO | USA | U01FD006879 | DEVELOPMENT AND QUALIFICATION OF A BIOMARKER FOR PRECLINICALLY IDENTIFYING THE PRO-ARRHYTHMIA RISK OF DRUGS BASED ON CONTRACTILITY MEASUREMENTS CONDUCTED IN HUMAN ADULT PRIMARY CARDIOMYOCYTES | 000 | 1 | FDA | 9/3/2019 | $247,461 |
| | 2019 | 2017 | ANABIOS CORPORATION | 3030 BUNKER HILL ST STE 312 | SAN DIEGO | CA | 92109-5754 | SAN DIEGO | USA | R44TR001133 | Validation and qualification of an ex vivo human cardiac tissue-based assay for the assessment of the potential cardiotoxicity of pharmaceutical compounds | 000 | 3 | NIH | 11/28/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $549,693 ) |
| | 2017 | 2017 | ANABIOS CORPORATION | 3030 BUNKER HILL ST STE 312 | SAN DIEGO | CA | 92109-5754 | SAN DIEGO | USA | R44TR001133 | Validation and qualification of an ex vivo human cardiac tissue-based assay for the assessment of the potential cardiotoxicity of pharmaceutical compounds | 000 | 3 | NIH | 6/23/2017 | $549,693 |
|
| Issue Date FY: 2016 ( Subtotal = $945,014 ) |
| | 2016 | 2016 | ANABIOS CORPORATION | 3030 BUNKER HILL ST STE 312 | SAN DIEGO | CA | 92109 | SAN DIEGO | USA | R44TR001133 | Validation and qualification of an ex vivo human cardiac tissue-based assay for the assessment of the potential cardiotoxicity of pharmaceutical compounds | 000 | 2 | NIH | 7/7/2016 | $945,014 |
|
| Issue Date FY: 2014 ( Subtotal = $200,651 ) |
| | 2014 | 2014 | ANABIOS CORPORATION | 3030 BUNKER HILL ST STE 312 | SAN DIEGO | CA | 92109 | SAN DIEGO | USA | R43TR001133 | Validation and qualification of an ex vivo human cardiac tissue-based assay for t | 000 | 1 | NIH | 6/24/2014 | $200,651 |
|
|
